Calcium glucoheptonate
Calcium glucoheptonate is an organic calcium salt. Calcium glucoheptonate promotes calcium uptake/mineralization. Calcium glucoheptonate increases Alkaline phosphatase activity and upregulates the expression of type I Collagen, Osteocalcin, Osteopontin, and SPARC. Calcium glucoheptonate stimulates the zona glomerulosa/fasciculata and inhibits the zona reticularis, inducing aldosterone/corticosterone secretion. Calcium glucoheptonate reduces body weight in middle-aged female rats. Calcium glucoheptonate can be used in research on calcium deficiency and menopausal symptoms.
For research use only. We do not sell to patients.
- CAS No.: 23351-51-1
- Formula: C7H14O8
- Molecular Weight:226.18
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
Calcium glucoheptonate (0.25-1.0 mM; 7 days) promotes calcium uptake and mineralization in MG-63 osteoblast-like cells, with a 30% increase at 1.0 mM[1].
Calcium glucoheptonate (0.25-1.0 mM; 7 days) increases total alkaline phosphatase activity in MG-63 osteoblast-like cells[1].
Calcium glucoheptonate (1.0 mM; 7 days) upregulates collagen type I (1.4-fold), osteocalcin (1.8-fold), and SPARC (1.5-fold) in MG-63 cells[1].
Calcium glucoheptonate (0.25-1.0 mM; 7 days) increases collagen-1, osteocalcin, and osteopontin protein levels in MG-63 osteoblast-like cells[1].
Calcium glucoheptonate (0.25-1.0 mM; 48 h) does not reduce Caco2 colorectal epithelial cell viability, with 88.80% and 110.35% viability at 0.25 and 1.0 mM[1].
Calcium glucoheptonate (0.25-1.0 mM; 48 h) does not induce cytotoxicity in HEK 293T kidney epithelial cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MG-63 osteoblast-like cells
-
Concentration:0.125, 0.25, 0.5, 1.0, 2.0, 4.0 mM calcium equivalents (MTT and trypan blue); 0.25, 1.0 mM calcium equivalents (AO/EB imaging)
-
Incubation Time:48 h
-
Result:Maximum proliferation was 157.35% of control at 0.25 mM.
1.0 and 2.0 mM also increased proliferation.
4.0 mM reduced viability relative to control.
Trypan blue counts followed a similar pattern, with reduced cell number at 4.0 mM.
At 0.25 and 1.0 mM, predominantly green viable nuclei with negligible red fluorescence were observed, indicating negligible cytotoxicity.
-
Cell Line:MG-63 osteoblast-like cells
-
Concentration:1.0 mM calcium equivalents
-
Incubation Time:7 days
-
Result:Collagen type I (1.4-fold), osteocalcin (1.8-fold), and SPARC (1.5-fold) gene expression were upregulated.
-
Cell Line:MG-63 osteoblast-like cells
-
Concentration:0.25 and 1.0 mM calcium equivalents
-
Incubation Time:7 days
-
Result:Osteopontin, osteocalcin, and collagen-1 expression increased at all tested concentrations compared with control.
Densitometric analysis normalized to β-actin confirmed higher levels of these proteins.
-
Cell Line:Caco2 colorectal epithelial cells
-
Concentration:0.25 and 1.0 mM calcium equivalents
-
Incubation Time:48 h
-
Result:Viability was 88.80% at 0.25 mM and 110.35% at 1.0 mM compared with untreated control.
-
Cell Line:HEK 293T kidney epithelial cells
-
Concentration:0.25 and 1.0 mM calcium equivalents
-
Incubation Time:48 h
-
Result:Viability remained similar to untreated control at both concentrations, with no cytotoxicity or adverse effect observed.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar (female, 14 months old, virgin, middle-aged)[2]
-
Dosage:11.4 mg/kg body weight
-
Administration:daily; for two weeks
-
Result:Pituitary weight was 35.3 mg.
Plasma FSH was 3.29 and plasma LH was 527.00.
FSH- and LH-immunoreactive cell perikarya were degranulated, and the examined morphometric parameters were decreased.
-
Animal Model:Wistar (female, 14 months old)[3]
-
Dosage:11.4 mg/kg b.w.
-
Administration:i.m.; once daily; 2 weeks
-
Result:Body weight was 306 g, 9.0% lower than control.
Absolute adrenal weight was 34.4 mg (−2.3%).
Relative adrenal weight was 11.2 mg/% (+6.7%).
Absolute and relative volumes of the zona glomerulosa and zona fasciculata were larger than in controls.
Absolute zona reticularis volume was 39.4% lower, and relative zona reticularis volume was 36.0% lower.
Total cell number increased by 20.6% in the zona glomerulosa and 41.1% in the zona fasciculata, while it was 63.7% lower in the zona reticularis.
Cell volume increased by 5.6% in the zona glomerulosa, decreased by 26.0% in the zona fasciculata, and decreased by 14.7% in the zona reticularis.
Serum aldosterone was 80.0% higher and serum corticosterone was 24.1% higher than in controls.
Chemical Information
-
CAS No. 23351-51-1
-
Molecular Weight 226.18
-
Formula C7H14O8
-
SMILES
OC(C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Calcium glucoheptonate Related Classifications
HY-W404758 Related Classifications
Powered by Bioz